Navigation Links
OncoSec Medical to Present at Industry and Investor Conferences
Date:8/24/2011

SAN DIEGO, Aug. 24, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be presenting a corporate overview at an upcoming investor conference and attending an industry event for medical devices.

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) BIOCOM Device Fest 2011Costa Mesa, CA, August 25Westin South Coast PlazaSouthern California Investor ConferenceNewport Beach, CA, August 29The Island HotelOncoSec Medical PresentationMichael Cross, Ph.D., Chief Business OfficerAbout OncoSec Medical Inc.OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Globus Medical Raises $110 Million in Series E Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- CVS Health Corporation (NYSE: CVS ) ... December 15, 2016, beginning at 8:00 a.m. (ET). Senior members ... in-depth review of the company,s strategies to drive long-term ... discuss 2017 earnings guidance during the event. ... be broadcast simultaneously on the Investor Relations portion of ...
(Date:12/2/2016)... 2, 2016 On Thursday, the NASDAQ ... red, while the Dow Jones Industrial Average managed to stay ... US markets, which prompted Stock-callers this morning to look at ... NUVA ), Smith & Nephew PLC (NYSE: ... ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ). ...
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, ... and the first company to offer robotic imaging to veterinary medicine is sponsoring ... # 941 for the American Association of Equine Practitioners 62nd Annual Convention from ...
(Date:12/2/2016)... ... ... "Pro3rd Accents Volume 2 is a set of 30 accented lower third ... a few clicks of the mouse," said Christina Austin - CEO of Pixel Film ... various styles with accented animations, rigid boxes, simplistic lines, and more. In Addition, users ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture of saliva ... teeth," said an inventor from Bridgewater, N.J. "I thought that there had to be ... , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, increasing ... public policymakers and system stakeholders in many states. To help them understand this ... Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a ...
Breaking Medicine News(10 mins):